Targeting mTOR with curcumin: therapeutic implications for complex diseases
- PMID: 39955697
- DOI: 10.1007/s10787-025-01643-y
Targeting mTOR with curcumin: therapeutic implications for complex diseases
Abstract
The mammalian target of rapamycin (mTOR) is a crucial enzyme in regulating multiple signaling pathways in the body, including autophagy, proliferation and apoptosis. Disruption of these mTOR signaling pathways can lead to an array of abnormalities and trigger disease processes, examples being neurodegenerative conditions, cancer, obesity and diabetes. Under conditions of oxidative stress, mTOR can regulate apoptosis and autophagy, with tissue repair being favored under such circumstances. Moreover, the correlation between mTOR and other signaling pathways could play a pivotal role in the pathophysiology of numerous disorders. mTOR has a tight connection with NF-κB, Akt, PI3K, MAPK, GSK-3β, Nrf2/HO-1, JAK/STAT, CREB/BDNF, and ERK1/2 pathways, which together could play significant roles in the regulation of inflammation, apoptosis, cell survival, and oxidative stress in different body organs. Research suggests that inhibiting mTOR could be beneficial in treating metabolic, neurological and cardiovascular conditions, as well as potentially extending life expectancy. Therefore, identifying new chemicals and agents that can modulate the mTOR signaling pathway holds promise for treating and preventing these disorders. Curcumin is one such agent that has demonstrated regulatory effects on the mTOR pathway, making it an exciting alternative for reducing complications associated with complex diseases by targeting mTOR. This review aims to examine the potential of curcumin in modulating the mTOR signaling pathway and its therapeutic implications.
Keywords: Curcuma longa; Inflammatory Signaling Pathways; Mammalian target of rapamycin (mTOR).
© 2025. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Conflict of interest statement
Declarations. Conflict of interest: None.
References
-
- Abuelezz NZ, Shabana ME, Abdel-Mageed HM, Rashed L, Morcos GNB (2020) Nanocurcumin alleviates insulin resistance and pancreatic deficits in polycystic ovary syndrome rats: Insights on PI3K/AkT/mTOR and TNF-α modulations. Life Sci 256:118003. https://doi.org/10.1016/j.lfs.2020.118003 - DOI - PubMed
-
- Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB (2007) Bioavailability of curcumin: problems and promises. Mol Pharm 4(6):807–818. https://doi.org/10.1021/mp700113r - DOI - PubMed
-
- Badr G, Gul HI, Yamali C, Mohamed AA, Badr BM, Gul M, Markeb AA, El-Maali NA (2018) Curcumin analogue 1, 5-bis (4-hydroxy-3-((4-methylpiperazin-1-yl) methyl) phenyl) penta-1, 4-dien-3-one mediates growth arrest and apoptosis by targeting the PI3K/AKT/mTOR and PKC-theta signaling pathways in human breast carcinoma cells. Bioorg Chem 78:46–57 - DOI - PubMed
-
- Bagheri H, Ghasemi F, Barreto GE, Rafiee R, Sathyapalan T, Sahebkar A (2020) Effects of curcumin on mitochondria in neurodegenerative diseases (Review). BioFactors 46(1):5–20. https://doi.org/10.1002/biof.1566 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous